3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Renal Cell
3
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Advanced Adult Hepatocellular Carcinoma
1
Interventions
Trastuzumab
243
Paclitaxel
193
Cyclophosphamide
158
Docetaxel
134
Letrozole
113
Capecitabine
113
Fulvestrant
106
Doxorubicin
103
Bevacizumab
87
Carboplatin
81
exemestane
80
Anastrozole
79
Lapatinib
70
Tamoxifen
69
Albumin-Bound Paclitaxel
57
palbociclib
54
pertuzumab
53
Taxes
51
Gemcitabine
50
Radiotherapy
46
eribulin
43
pembrolizumab
41
Everolimus
41
Ado-Trastuzumab Emtansine
41
Vinorelbine
38
130-nm albumin-bound paclitaxel
35
ixabepilone
32
Epirubicin
28
pegfilgrastim
25
liposomal doxorubicin
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Breast Neoplasms
×
tivozanib
×
Clear all
NCT01745367
2020-10-27
BATON-BC
AVEO Pharmaceuticals, Inc.
Phase 2
Terminated
30 enrolled
10 charts